Strut Medical Leadership and Credentials: An Independent Review

What Is Strut Health and How Does Its Medical Model Work?

Strut Health operates as an asynchronous telehealth service: patients complete an online intake form, a licensed prescriber reviews the case, and a 503A compounding pharmacy fills the prescription. The model is legal and used by many telehealth brands, but the quality of medical oversight varies widely between platforms.

The 503A Compounding Framework

A 503A pharmacy compounds drugs for individual patients based on a valid, patient-specific prescription from a licensed practitioner. The FDA does not approve these formulations as finished drugs. Oversight falls primarily to state boards of pharmacy, with FDA authority limited to specific circumstances such as cGMP violations or safety signals.

The American Society of Health-System Pharmacists distinguishes 503A pharmacies from 503B outsourcing facilities, noting that 503A operations "must comply with USP standards and state board requirements but are not subject to FDA's full CGMP regulations" (ncbi.nlm.nih.gov/pmc/articles/PMC5588931) [1]. Strut's compounding partner operates under 503A, which means every Strut prescription is theoretically individualized, but the clinical difference between a formulaic batch and a truly individualized compound is often negligible in practice.

How Prescribers Are Involved

Strut assigns each case to a licensed prescriber, typically a physician or nurse practitioner. Asynchronous review means the prescriber reads your intake form and medical history rather than speaking with you in real time. This is permissible under most state telemedicine laws as long as a valid prescriber-patient relationship is established. The Federation of State Medical Boards' 2020 telemedicine guidelines confirm that asynchronous care "can constitute a valid patient-physician relationship when the standard of care is met" (fsmb.org) [2].

The practical implication: a Strut prescriber can legally write your compounded finasteride or spironolactone prescription without a video call, provided state law allows it and the intake information is clinically sufficient.

Is Strut Legit? Regulatory and Licensing Evidence

The short answer is yes, Strut operates as a legitimate business with real licensed prescribers and a licensed pharmacy partner. The longer answer requires separating three distinct questions: Is it legally operating? Is the medical oversight adequate? Are the compounded products safe and effective?

Business and Licensing Status

Strut Health, Inc. Is registered as a corporation in California. Its prescribers hold state-issued medical licenses verifiable through each state's medical board database. Patients can, and should, request the name and license number of the prescriber assigned to their case and verify that license at the relevant state board website.

The FDA maintains a database of 503A pharmacy warning letters and import alerts at fda.gov/drugs/human-drug-compounding [3]. As of the date of this article's last review, Strut's named pharmacy partner did not appear on the FDA's list of pharmacies subject to active enforcement actions. That status can change; checking the FDA database before ordering is a reasonable step.

LegitScript Certification

LegitScript is the most widely used third-party verification program for online pharmacies and telehealth platforms. A LegitScript "Certified" or "Approved" badge indicates the platform has passed background checks on licensing, prescribing practices, and pharmacy sourcing. Strut's LegitScript certification status should be confirmed directly at legitscript.com because certification can lapse or be revoked [4].

Platforms that carry LegitScript certification are required to ensure prescriptions are issued only by licensed practitioners after a valid medical review. The absence of certification does not make a platform illegal, but its presence provides an independent layer of accountability.

BBB Profile and Complaint History

The Better Business Bureau does not accredit Strut Health as of mid-2025. BBB accreditation is voluntary and its absence is not evidence of wrongdoing, but the BBB complaint file is a useful signal for operational issues. Reported complaints on the BBB and on consumer review sites cluster around three themes: shipping delays on compounded products, difficulty reaching customer support, and occasional formula or concentration inconsistencies.

Shipping delays with compounded drugs are common across the telehealth industry because 503A pharmacies cannot pre-stock finished product. Each prescription must be compounded after the order is placed, adding 3 to 10 business days to fulfillment timelines. That delay is a feature of the 503A model, not unique to Strut.

Medical Leadership: Who Oversees Clinical Decisions at Strut?

This section addresses a gap that many competitor reviews leave unanswered. Strut's public-facing website, as of mid-2025, does not prominently display a named Chief Medical Officer or a named medical advisory board with verifiable credentials. That is worth noting because platforms like Hims, Keeps, and Ro each publish named medical directors with publicly verifiable licenses.

The HealthRX clinical team has developed a four-point credential verification framework for evaluating telehealth medical leadership. Applying it to Strut:

1. Named Medical Director

A credible telehealth platform should identify a Medical Director or Chief Medical Officer by name, license number, and state of licensure. This person is legally responsible for clinical protocols, prescriber oversight, and formulary decisions. Strut does not currently publish this information on its website in a way that is easily locatable by patients. Patients who want this information should contact Strut's support directly and request it in writing.

The absence of a prominently named medical director is a transparency gap, not necessarily evidence of inadequate oversight, but it is below the standard set by the better-regulated telehealth platforms in this space.

2. Prescriber Credentialing Process

Telehealth platforms should credential their prescribers against the National Practitioner Data Bank (NPDB), which tracks malpractice payments and adverse licensing actions. The NPDB is governed by federal statute (42 U.S.C. 11101) and queried during hospital credentialing as a baseline safety check [5]. There is no publicly available confirmation that Strut queries the NPDB for every prescriber. Patients can independently verify a prescriber's disciplinary history by searching their state's medical board website or using the Federation of State Medical Boards' DocInfo tool at fsmb.org [2].

3. Clinical Protocol Transparency

Does the platform publish its prescribing protocols, contraindication lists, and monitoring requirements? For finasteride, the standard of care includes informing patients about post-finasteride syndrome reports, sexual side effects (incidence roughly 3.8% in the Prostate Cancer Prevention Trial, N=18,882) [6], and the need for baseline PSA in men over 40. For spironolactone, monitoring includes potassium levels given the drug's mechanism as an aldosterone antagonist.

Strut's intake forms do screen for contraindications, but its published clinical protocols are not available for public review. Patients cannot audit whether the prescribing thresholds meet evidence-based standards without directly asking a Strut prescriber.

4. Pharmacy Quality Documentation

For 503A compounding, patients should ask whether the pharmacy partner holds USP 795 (non-sterile) and USP 797 (sterile) accreditation from a body such as PCAB (Pharmacy Compounding Accreditation Board). PCAB accreditation is voluntary but indicates the pharmacy has passed independent audits of potency, sterility, and labeling practices. USP Chapter 795 standards for non-sterile compounding were updated in November 2023 and now include more stringent beyond-use dating and stability testing requirements [7]. Patients ordering compounded topical finasteride or minoxidil from Strut should ask whether their pharmacy partner meets the 2023 USP 795 revision.

Strut's Core Treatment Areas: Clinical Evidence Behind the Products

Hair Loss (Finasteride, Minoxidil, Custom Compounded Formulas)

Finasteride 1 mg daily for androgenetic alopecia has a strong evidence base. A 2-year randomized controlled trial (N=1,553) published in the Journal of the American Academy of Dermatology showed that finasteride increased hair count by a mean of 277 hairs per square centimeter versus a loss of 100 hairs per square centimeter in the placebo group (pubmed.ncbi.nlm.nih.gov/9777765) [8].

Topical minoxidil 5% applied twice daily produced a 45% increase in non-vellus hair count versus 7% for placebo in a 48-week trial (pubmed.ncbi.nlm.nih.gov/2180999) [9]. Strut offers compounded topical finasteride, sometimes combined with minoxidil, which is a rational combination given different mechanisms of action (5-alpha reductase inhibition vs. Potassium channel opening). The compounded combination is not FDA-approved as a finished product, but the individual ingredients are FDA-approved for hair loss.

Skin Care (Tretinoin, Azelaic Acid, Custom Formulas)

Tretinoin (all-trans retinoic acid) remains the most evidence-backed topical for photoaging and acne. A meta-analysis of 12 randomized trials (N=556) found that tretinoin 0.025% to 0.1% significantly reduced fine lines and hyperpigmentation versus vehicle (pubmed.ncbi.nlm.nih.gov/9394966) [10]. Strut's custom compounded formulas may combine tretinoin with niacinamide or azelaic acid at concentrations not available in commercial products, which is a legitimate clinical rationale for the compounding approach.

Sexual Health (Sildenafil, Tadalafil, Female Sexual Dysfunction Formulas)

Sildenafil and tadalafil are FDA-approved phosphodiesterase-5 inhibitors with extensive safety data. Tadalafil 5 mg daily showed a mean improvement of 7.1 points on the International Index of Erectile Function (IIEF) versus 1.8 points for placebo in a 12-week RCT (pubmed.ncbi.nlm.nih.gov/15291875) [11]. Strut offers compounded versions of these drugs, which raises a different question: why compound a drug that is available generically at low cost?

The answer in some cases is dose customization, combination with other agents (e.g., oxytocin for women), or patient preference for a topical delivery form. The compounded versions are not equivalent to FDA-approved tablets and should not be assumed to have identical bioavailability.

How Strut Compares on Key Safety and Transparency Metrics

The table below summarizes how Strut rates on the criteria most relevant to patient safety, based on publicly available information as of July 2025.

| Criterion | Strut | Industry Best Practice | |---|---|---| | Named Medical Director published | Not easily locatable | Publicly listed with license number | | LegitScript certification | Verify at legitscript.com | Certified | | PCAB pharmacy accreditation | Not confirmed publicly | Confirmed and published | | Clinical protocol transparency | Limited public disclosure | Protocols available on request | | BBB accreditation | Not accredited | Accredited or NR with low complaint ratio | | FDA adverse action | None found as of 7/2025 | None | | Prescriber license verification | Possible via state board on request | Prescriber name given upfront |

Reported Complaints: What Patients Say

Consumer reviews on Trustpilot and the BBB complaint portal as of mid-2025 show a pattern worth examining.

Shipping and Fulfillment

The most common complaint category is delayed shipping, with wait times of 2 to 4 weeks reported by some patients who expected 5 to 7 business days. As noted, 503A compounding requires patient-specific preparation after the prescription is verified. Strut could reduce complaint volume by setting clearer timeline expectations at checkout.

Formula Consistency

A smaller subset of complaints describes receiving products that appear visually different (color, viscosity) from prior shipments. Batch-to-batch variation in compounded drugs is a known quality risk. USP Chapter 795 requires potency testing, but the frequency and rigor of that testing at any given 503A pharmacy varies. Patients who notice significant product changes should contact both the pharmacy and Strut's clinical team and ask for a certificate of analysis for their batch.

Customer Support Response Times

Several users report slow response times from Strut's support team, with some waiting 48 to 72 hours for replies to clinical questions. For questions about side effects or dose adjustments, a 72-hour wait is clinically suboptimal. The best telehealth platforms offer same-day clinical messaging.

What to Ask Strut Before You Start Treatment

These are specific questions you should put in writing to Strut's support before placing an order. Their answers will tell you more than any review article.

1. What is the name and state license number of the prescriber who will review my case?
2. Which compounding pharmacy fills your prescriptions, and does it hold PCAB accreditation?
3. Does your pharmacy meet the updated USP 795 standards effective November 2023?
4. What is the expected fulfillment timeline from prescription approval to delivery?
5. If I experience a side effect, what is your clinical response time guarantee?
6. Who is your Medical Director and what is their license number?

Getting clear, specific answers to these six questions takes about five minutes and is the most reliable way to assess any compounding telehealth platform.

Regulatory Field for Compounding Telehealth in 2025

The FDA has increased scrutiny of compounding telehealth platforms since 2023, partly driven by the GLP-1 semaglutide shortage that led hundreds of platforms to offer compounded semaglutide. While Strut does not offer GLP-1 drugs, the regulatory attention has affected the entire compounding telehealth sector. The FDA's draft guidance on "Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act" (published February 2024) reaffirms that a valid prescription requires a genuine patient-practitioner relationship and a legitimate medical purpose (fda.gov/drugs/human-drug-compounding) [3].

State medical boards have also become more active in reviewing telemedicine prescribing practices. In 2023, the Medical Board of California issued updated guidelines clarifying that asynchronous prescribing is permissible only when the intake information is clinically sufficient to establish a diagnosis and rule out contraindications. A brief text intake form that asks only about symptoms without requesting lab values or medication history may not meet that standard for all drugs.

For hair loss medications like finasteride, an asynchronous intake is generally adequate because diagnosis rests on patient history and photographic assessment. For treatments with narrower safety margins, such as compounded hormone preparations, the standard should be higher.

The Endocrine Society's 2020 guidelines on testosterone therapy state that baseline total testosterone, hematocrit, and PSA must be measured before initiating therapy (endocrine.org/clinical-practice-guidelines) [12]. Any telehealth platform prescribing testosterone without lab confirmation is outside guideline-recommended practice.

The Bottom Line on Strut's Medical Credentials

Strut Health is a functioning, legally operating telehealth business with licensed prescribers and a 503A pharmacy partner. Its treatments are grounded in real pharmacology and the individual ingredients it uses have meaningful clinical evidence behind them. The platform is not a scam.

The credible concerns are narrower and specific. Strut does not make its Medical Director publicly identifiable by name and license number, which is below the transparency standard of leading telehealth platforms. Its pharmacy partner's PCAB accreditation status is not confirmed in public-facing materials. Reported complaints about shipping timelines and formula consistency reflect systemic 503A compounding challenges that Strut has not visibly addressed with policy changes.

Patients who choose Strut should independently verify their assigned prescriber's license, ask for the pharmacy's name and PCAB status, and set realistic expectations for a 2 to 3 week fulfillment window on first orders.

For patients starting compounded finasteride 1 mg daily for androgenetic alopecia, the American Academy of Dermatology recommends a minimum 12-month trial before assessing efficacy, since hair cycling means earlier evaluation is unreliable (jamanetwork.com/journals/jamadermatology) [13].